Hemocompatibility of amyloid and/or brain targeted liposomes
Targeted liposomes with different combinations of five ligands (for brain/amyloid targeting) were evaluated for hemocompatibility. Results reveal that all liposomes studied, caused minimum hemolysis; targeted liposomes slightly reduced blood coagulation time, but not significantly more than control liposomes; and compliment factors SC5b9 and iC3b increased when compared with the buffer, by most targeted liposomes. However, the specific amounts of both factors were similar with those induced by control liposomes. Thus, the targeted liposomes are unanticipated to cause hypersensitivity problems. Good correlations between vesicle size and produced factor amounts were observed. In conclusion, the current targeted liposomes are not expected to cause serious blood toxicity, if used in vivo.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Future medicinal chemistry - 11(2019), 7 vom: 28. Apr., Seite 693-705 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Michanetzis, Georgios Pa [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 03.03.2020 Date Revised 03.03.2020 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.4155/fmc-2018-0236 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM295858036 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM295858036 | ||
| 003 | DE-627 | ||
| 005 | 20231225084556.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4155/fmc-2018-0236 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0986.xml |
| 035 | |a (DE-627)NLM295858036 | ||
| 035 | |a (NLM)30964329 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Michanetzis, Georgios Pa |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Hemocompatibility of amyloid and/or brain targeted liposomes |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.03.2020 | ||
| 500 | |a Date Revised 03.03.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Targeted liposomes with different combinations of five ligands (for brain/amyloid targeting) were evaluated for hemocompatibility. Results reveal that all liposomes studied, caused minimum hemolysis; targeted liposomes slightly reduced blood coagulation time, but not significantly more than control liposomes; and compliment factors SC5b9 and iC3b increased when compared with the buffer, by most targeted liposomes. However, the specific amounts of both factors were similar with those induced by control liposomes. Thus, the targeted liposomes are unanticipated to cause hypersensitivity problems. Good correlations between vesicle size and produced factor amounts were observed. In conclusion, the current targeted liposomes are not expected to cause serious blood toxicity, if used in vivo | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Alzheimer's disease | |
| 650 | 4 | |a amyloid | |
| 650 | 4 | |a complement activation | |
| 650 | 4 | |a curcumin | |
| 650 | 4 | |a hemocompatibility | |
| 650 | 4 | |a hemolysis | |
| 650 | 4 | |a liposome | |
| 650 | 4 | |a monoclonal antibody | |
| 650 | 4 | |a nanoparticle | |
| 650 | 4 | |a targeting | |
| 650 | 7 | |a Amyloid |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 650 | 7 | |a ApoE protein, human |2 NLM | |
| 650 | 7 | |a Apolipoproteins E |2 NLM | |
| 650 | 7 | |a Biocompatible Materials |2 NLM | |
| 650 | 7 | |a Complement Membrane Attack Complex |2 NLM | |
| 650 | 7 | |a Ethanolamines |2 NLM | |
| 650 | 7 | |a Liposomes |2 NLM | |
| 650 | 7 | |a Phosphatidylcholines |2 NLM | |
| 650 | 7 | |a SC5b-9 protein complex |2 NLM | |
| 650 | 7 | |a phosphorylethanolamine |2 NLM | |
| 650 | 7 | |a 78A2BX7AEU |2 NLM | |
| 650 | 7 | |a Complement C3b |2 NLM | |
| 650 | 7 | |a 80295-43-8 |2 NLM | |
| 650 | 7 | |a Curcumin |2 NLM | |
| 650 | 7 | |a IT942ZTH98 |2 NLM | |
| 700 | 1 | |a Markoutsa, Eleni |e verfasserin |4 aut | |
| 700 | 1 | |a Mourtas, Spyridon |e verfasserin |4 aut | |
| 700 | 1 | |a Missirlis, Yannis F |e verfasserin |4 aut | |
| 700 | 1 | |a Antimisiaris, Sophia G |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Future medicinal chemistry |d 2009 |g 11(2019), 7 vom: 28. Apr., Seite 693-705 |w (DE-627)NLM194822109 |x 1756-8927 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2019 |g number:7 |g day:28 |g month:04 |g pages:693-705 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4155/fmc-2018-0236 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2019 |e 7 |b 28 |c 04 |h 693-705 | ||